AN2 Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	19.94	21.35	15.65	27.22	12.1
Short-Term Investments	38.06	62.27	91.65	68.84	46.46
Cash & Short-Term Investments	58	83.62	107.3	96.06	58.56
Cash Growth	-30.64%	-22.07%	11.70%	64.05%	1338.70%
Other Current Assets	1.94	2.64	3.21	2.51	1.55
Total Current Assets	59.94	86.26	110.51	98.62	60.11
Net Property, Plant & Equipment	-	-	-	0.05	-
Long-Term Investments	2.01	5.02	27.19	3.22	3.49
Other Long-Term Assets	-	0.8	1.04	0.72	1.72
Total Assets	61.95	92.09	138.74	102.56	65.32
Accounts Payable	3.02	3.32	2.68	2.12	1.06
Accrued Expenses	4.47	6.13	10.7	5.01	2.32
Current Portion of Leases	-	-	-	0.05	-
Other Current Liabilities	1.23	0.79	0.67	0.01	0.02
Total Current Liabilities	8.72	10.24	14.04	7.19	3.4
Other Long-Term Liabilities	-	-	-	0	0.01
Total Long-Term Liabilities	-	-	-	0	0.01
Total Liabilities	8.89	10.24	14.04	7.19	3.41
Additional Paid-in Capital	293.95	287.59	278.88	185.47	-
Accumulated Other Comprehensive Income	0.06	0.03	0.28	-0.37	-0.03
Retained Earnings	-240.95	-205.78	-154.46	-89.72	-47.38
Total Common Shareholders' Equity	53.06	81.85	124.7	95.37	-47.41
Shareholders' Equity	53.06	81.85	124.7	95.37	109.32
Total Liabilities & Equity	61.95	92.09	138.74	102.56	65.32
Total Debt	0	0	0	0.05	0
Net Cash (Debt)	58	83.62	107.3	96.01	58.56
Net Cash Growth	-30.64%	-22.07%	11.76%	63.96%	1338.70%
Net Cash Per Share	1.92	2.80	4.55	6.26	22.20
Book Value	53.06	81.85	124.7	95.37	-47.41
Book Value Per Share	1.76	2.74	5.28	6.22	-17.97
Tangible Book Value	53.06	81.85	124.7	95.37	-47.41
Tangible Book Value Per Share	1.76	2.74	5.28	6.22	-17.97

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q